Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC-Reference-Cited by-同舟云学术

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Published:2024-06-26 Issue: Volume: Page:
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Cho Byoung C.¹^ORCID,Lu Shun¹,Felip Enriqueta¹,Spira Alexander I.¹,Girard Nicolas¹,Lee Jong-Seok¹,Lee Se-Hoon¹,Ostapenko Yurii¹,Danchaivijitr Pongwut¹,Liu Baogang¹,Alip Adlinda¹,Korbenfeld Ernesto¹,Mourão Dias Josiane¹,Besse Benjamin¹,Lee Ki-Hyeong¹,Xiong Hailin¹,How Soon-Hin¹,Cheng Ying¹,Chang Gee-Chen¹,Yoshioka Hiroshige¹,Yang James C.-H.¹,Thomas Michael¹,Nguyen Danny¹,Ou Sai-Hong I.¹,Mukhedkar Sanjay¹,Prabhash Kumar¹,D’Arcangelo Manolo¹,Alatorre-Alexander Jorge¹,Vázquez Limón Juan C.¹,Alves Sara¹,Stroyakovskiy Daniil¹,Peregudova Marina¹,Şendur Mehmet A.N.¹,Yazici Ozan¹,Califano Raffaele¹,Gutiérrez Calderón Vanesa¹,de Marinis Filippo¹,Passaro Antonio¹^ORCID,Kim Sang-We¹,Gadgeel Shirish M.¹,Xie John¹,Sun Tao¹,Martinez Melissa¹,Ennis Mariah¹,Fennema Elizabeth¹,Daksh Mahesh¹,Millington Dawn¹,Leconte Isabelle¹,Iwasawa Ryota¹,Lorenzini Patricia¹,Baig Mahadi¹,Shah Sujay¹,Bauml Joshua M.¹,Shreeve S. Martin¹,Sethi Seema¹,Knoblauch Roland E.¹,Hayashi Hidetoshi¹^ORCID

Affiliation:

1. From the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Samsung Medical Center, Sungkyunkwan University School of Medicine (S.-H.L.), and the Lung Cancer Center, Asan Medical Center Cancer Institute (S.-W.K.), Seoul, the Department of Hematology–Oncology, Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and the Medical Department, Chungbuk National University Hospital, Cheongju (K.-H.L.) — all in South Korea; the Department of...

Funder

Janssen Research & Development, LLC

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2403614

Reference38 articles.

1. New driver mutations in non-small-cell lung cancer

2. Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

3. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

4. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

5. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the Need for Better Information from Randomized Clinical Trials in Oncology;2024-09-03

2. EGFR-mutated NSCLC: A roadmap to treatment sequences;Med;2024-09

3. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA;Annals of Oncology;2024-09

4. The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC;Nature Reviews Clinical Oncology;2024-08-19

5. An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2024-08